Journal of International Psychiatry

[Abstract] Objective To observe the effect of donepezil combined with quetiapine on cognitive function and psychiatric symptoms in patients with Alzheimers disease. Methods A total of 100 patients with Alzheimers disease who were admitted to our hospital from July 2011 to July 2018 were randomly divided into experimental group and control group. There were cases in which both groups fell off due to adverse drug reactions or loss of follow-up. In the final experimental group, 48 patients were enrolled and 47 patients in the control group were enrolled. The experimental group was treated with donepezil plus quetiapine, and the control group was treated with donepezil plus olanzapine. Both groups were treated for 12 weeks. The cognitive function was evaluated by Mini-mental State Examination before treatment and after 12 weeks of treatment. The psychotic symptoms of the two groups were evaluated before and 12 weeks after treatment with the Behavioralpathology Alzheimer’ sdisease. The overall incidence of adverse reactions during the two treatment periods was compared between two groups. Results The MMSE scores of the two groups after 12 weeks of treatment were higher than those before treatment, and the BEHAVE-AD score was lower than that before treatment (P<0.05). There was no significant difference in BEHAVE-AD score and MMSE score between the observation group and the control group after 12 weeks of treatment (P>0.05). The total incidence of adverse reactions in the experimental group was 20.83%, which was lower than 40.43% in the control group(P<0.05). Conclusion Donepezil combined with quetiapine and donepezil combined with olanzapine can improve cognitive function and psychiatric symptoms. Among them, donepezil combined with quetiapine has less impact on sleep and respiratory function, and has higher safety.